Among the best clinically documented is the DC/AML fusion vaccine, an autologous fusion of DCs with leukemia cells, demonstrating safety, the ability to activate CD8+ T cells, and control MRD [194]. The gene discussed is CD8A; the disease is acute myeloid leukemia.